Titre : ADP ribose transferases

ADP ribose transferases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Gain of Function Mutation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "ADP ribose transferases : Questions médicales les plus fréquentes", "headline": "ADP ribose transferases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les ADP ribose transferases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-30", "dateModified": "2025-04-24", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "ADP ribose transferases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pentosyltransferases", "url": "https://questionsmedicales.fr/mesh/D010430", "about": { "@type": "MedicalCondition", "name": "Pentosyltransferases", "code": { "@type": "MedicalCode", "code": "D010430", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "NAD nucleosidase", "alternateName": "NAD+ Nucleosidase", "url": "https://questionsmedicales.fr/mesh/D009244", "about": { "@type": "MedicalCondition", "name": "NAD nucleosidase", "code": { "@type": "MedicalCode", "code": "D009244", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.660" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "ADP-ribosyl cyclase", "alternateName": "ADP-ribosyl Cyclase", "url": "https://questionsmedicales.fr/mesh/D036541", "about": { "@type": "MedicalCondition", "name": "ADP-ribosyl cyclase", "code": { "@type": "MedicalCode", "code": "D036541", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.660.060" } } } ] }, { "@type": "MedicalWebPage", "name": "Poly(ADP-ribose) polymerases", "alternateName": "Poly(ADP-ribose) Polymerases", "url": "https://questionsmedicales.fr/mesh/D011065", "about": { "@type": "MedicalCondition", "name": "Poly(ADP-ribose) polymerases", "code": { "@type": "MedicalCode", "code": "D011065", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Poly (ADP-Ribose) polymerase-1", "alternateName": "Poly (ADP-Ribose) Polymerase-1", "url": "https://questionsmedicales.fr/mesh/D000071137", "about": { "@type": "MedicalCondition", "name": "Poly (ADP-Ribose) polymerase-1", "code": { "@type": "MedicalCode", "code": "D000071137", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690.420" } } }, { "@type": "MedicalWebPage", "name": "Tankyrases", "alternateName": "Tankyrases", "url": "https://questionsmedicales.fr/mesh/D038501", "about": { "@type": "MedicalCondition", "name": "Tankyrases", "code": { "@type": "MedicalCode", "code": "D038501", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.913.400.725.115.690.840" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "ADP ribose transferases", "alternateName": "ADP Ribose Transferases", "code": { "@type": "MedicalCode", "code": "D036002", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anthony K L Leung", "url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA." } }, { "@type": "Person", "name": "Morgan Dasovich", "url": "https://questionsmedicales.fr/author/Morgan%20Dasovich", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA." } }, { "@type": "Person", "name": "Mohsen Badiee", "url": "https://questionsmedicales.fr/author/Mohsen%20Badiee", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205." } }, { "@type": "Person", "name": "Yong Zhang", "url": "https://questionsmedicales.fr/author/Yong%20Zhang", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States." } }, { "@type": "Person", "name": "Sua Myong", "url": "https://questionsmedicales.fr/author/Sua%20Myong", "affiliation": { "@type": "Organization", "name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Case report: Myocarditis in congenital STAT1 gain-of function.", "datePublished": "2023-03-20", "url": "https://questionsmedicales.fr/article/37020552", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1095595" } }, { "@type": "ScholarlyArticle", "name": "Neuronal actin cytoskeleton gain of function in the human brain.", "datePublished": "2023-07-28", "url": "https://questionsmedicales.fr/article/37517100", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ebiom.2023.104725" } }, { "@type": "ScholarlyArticle", "name": "A Heterozygous Gain-of-Function Variant in IKBKB Associated with Autoimmunity and Autoinflammation.", "datePublished": "2022-11-15", "url": "https://questionsmedicales.fr/article/36378426", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10875-022-01395-2" } }, { "@type": "ScholarlyArticle", "name": "KCNA1 gain-of-function epileptic encephalopathy treated with 4-aminopyridine.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36793218", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/acn3.51742" } }, { "@type": "ScholarlyArticle", "name": "Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis.", "datePublished": "2022-09-12", "url": "https://questionsmedicales.fr/article/36172362", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.983977" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Transferases", "item": "https://questionsmedicales.fr/mesh/D014166" }, { "@type": "ListItem", "position": 5, "name": "Glycosyltransferase", "item": "https://questionsmedicales.fr/mesh/D016695" }, { "@type": "ListItem", "position": 6, "name": "Pentosyltransferases", "item": "https://questionsmedicales.fr/mesh/D010430" }, { "@type": "ListItem", "position": 7, "name": "ADP ribose transferases", "item": "https://questionsmedicales.fr/mesh/D036002" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : ADP ribose transferases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur ADP ribose transferases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur ADP ribose transferases", "description": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?\nQuels marqueurs biochimiques sont associés aux ADP ribose transferases ?\nY a-t-il des tests spécifiques pour les ADP ribose transferases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests d'imagerie sont-ils utiles pour ces enzymes ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur ADP ribose transferases", "description": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?\nPeut-on observer des symptômes neurologiques ?\nLes symptômes varient-ils selon le type d'enzyme ?\nY a-t-il des symptômes cutanés associés ?\nLes symptômes sont-ils toujours présents ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur ADP ribose transferases", "description": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'exercice physique aide-t-il à prévenir ces dysfonctionnements ?\nLes vaccinations ont-elles un rôle préventif ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur ADP ribose transferases", "description": "Quels traitements existent pour les dysfonctionnements enzymatiques ?\nLes suppléments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements sont-ils curatifs ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur ADP ribose transferases", "description": "Quelles complications peuvent survenir avec ces dysfonctionnements ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies cardiovasculaires ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles prévisibles ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur ADP ribose transferases", "description": "Quels sont les principaux facteurs de risque ?\nL'âge est-il un facteur de risque ?\nLe stress a-t-il un impact sur ces enzymes ?\nLes antécédents familiaux influencent-ils le risque ?\nL'alimentation joue-t-elle un rôle ?", "url": "https://questionsmedicales.fr/mesh/D036002?mesh_terms=Gain+of+Function+Mutation&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des ADP ribose transferases ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour évaluer leur activité." } }, { "@type": "Question", "name": "Quels marqueurs biochimiques sont associés aux ADP ribose transferases ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux d'ADP-ribose libre et de protéines modifiées peuvent servir de marqueurs." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour les ADP ribose transferases ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la réparation de l'ADN ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les tests d'imagerie sont-ils utiles pour ces enzymes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, les tests d'imagerie ne sont pas utilisés pour diagnostiquer les dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une déficience en ADP ribose transferases ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la réparation de l'ADN, des maladies neurodégénératives et des cancers." } }, { "@type": "Question", "name": "Peut-on observer des symptômes neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs et des problèmes de mémoire peuvent survenir." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type d'enzyme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, différents types d'ADP ribose transferases peuvent entraîner des symptômes variés." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître en raison de troubles métaboliques liés aux enzymes." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains patients peuvent être asymptomatiques malgré une dysfonction enzymatique." } }, { "@type": "Question", "name": "Peut-on prévenir les dysfonctionnements des ADP ribose transferases ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines et à des radiations peut affecter l'activité enzymatique." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages peuvent être utiles pour les personnes à risque élevé de maladies associées." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à prévenir ces dysfonctionnements ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé cellulaire et enzymatique." } }, { "@type": "Question", "name": "Les vaccinations ont-elles un rôle préventif ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, les vaccinations ne sont pas directement liées à la prévention des dysfonctionnements enzymatiques." } }, { "@type": "Question", "name": "Quels traitements existent pour les dysfonctionnements enzymatiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblés peuvent être envisagés." } }, { "@type": "Question", "name": "Les suppléments peuvent-ils aider ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des suppléments d'ADP-ribose peuvent être envisagés, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques sur des inhibiteurs spécifiques des ADP ribose transferases sont en cours." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du type de dysfonctionnement enzymatique." } }, { "@type": "Question", "name": "Les traitements sont-ils curatifs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Non, la plupart des traitements visent à gérer les symptômes plutôt qu'à guérir la condition." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces dysfonctionnements ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des cancers, des maladies auto-immunes et des troubles neurologiques peuvent se développer." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies cardiovasculaires ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent un lien entre dysfonctionnement enzymatique et maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction des antécédents médicaux." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, l'exposition à des toxines et le mode de vie jouent un rôle." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur ces enzymes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut altérer l'activité des ADP ribose transferases." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies liées peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire le risque de dysfonctionnement enzymatique." } } ] } ] }

Sources (10000 au total)

Neuronal actin cytoskeleton gain of function in the human brain.

While advancements in imaging techniques have led to major strides in deciphering the human brain, successful interventions are elusive and represent some of the most persistent translational gaps in ... The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples. The emerging pathways and mechanistic hypotheses are tested and v... CHRFAM7A is identified as a modulator of intracellular calcium dynamics and an upstream regulator of Rac1. Rac1 activation re-designs the actin cytoskeleton leading to dynamic actin driven remodeling ... CHRFAM7A modifies the actin cytoskeleton to a more dynamic and stiffness resistant state in an α7nAChR dependent manner. CHRFAM7A may facilitate neuronal adaptation to changes in the brain environment... This work is supported in part by the Community Foundation for Greater Buffalo (Kinga Szigeti). Also, in part by the International Society for Neurochemistry (ISN) and The Company of Biologists (Nicol...

A Heterozygous Gain-of-Function Variant in IKBKB Associated with Autoimmunity and Autoinflammation.

Biallelic loss-of-function variants in IKBKB cause severe combined immunodeficiency. We describe a case of autoimmunity and autoinflammation in a male infant with a heterozygous gain-of-function (GOF)... Case report and review of the literature. We performed in silico variant analysis, measurement of plasma soluble biomarkers associated with immune activation, functional stimulation of patient periphe... A patient with two heterozygous IKBKB variants (E518K and T559M) presents with previously undescribed autoimmune cytopenias and autoinflammation. He had decreased TNF-α-induced IkBα degradation in vit... A GOF variant in IKBKB may associate with autoinflammation and autoimmunity highlighting a novel clinical phenotype....

A gain-of-function variation in PLCG1 causes a new immune dysregulation disease.

Phospholipase C (PLC) γ1 is a critical enzyme regulating nuclear factor-κB (NF-κB), extracellular signal-related kinase, mitogen-activated protein kinase, and nuclear factor of activated T cells signa... We aimed to investigate the molecular pathogenesis of a PLCG1 activating variant in a patient with immune dysregulation.... Whole exome sequencing was used to identify the patient's pathogenic variants. Bulk RNA sequencing, single-cell RNA sequencing, quantitative PCR, cytometry by time of flight, immunoblotting, flow cyto... We identified a novel and de novo heterozygous PLCG1 variant, p.S1021F, in a patient presenting with early-onset immune dysregulation disease. We demonstrated that the S1021F variant is a gain-of-func... Our study highlights the critical role of PLCγ1 in maintaining immune homeostasis. We illustrate immune dysregulation as a consequence of PLCγ1 activation and provide insight into therapeutic targetin...